These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 4556618)

  • 1. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Parkinson's disease with amantadine].
    Sigwald J; Raymondeaud C; Grégoire J
    Therapeutique; 1972 Nov; 48(9):555-60. PubMed ID: 4568230
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of parkinsonism by amantadine and levodopa.
    Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE
    Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584
    [No Abstract]   [Full Text] [Related]  

  • 4. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
    Schwab RS; England AC
    Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 6. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M; Jorgensen PB
    Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome.
    Fehling C
    Acta Neurol Scand; 1973; 49(2):245-51. PubMed ID: 4577929
    [No Abstract]   [Full Text] [Related]  

  • 10. Amantadine and levodopa in the treatment of Parkinson's disease.
    Walker JE; Potvin A; Tourtellotte W; Albers J; Repa B; Henderson W; Snyder D
    Clin Pharmacol Ther; 1972; 13(1):28-36. PubMed ID: 4550321
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
    Parkes JD; Baxter RC; Curzon G; Knill-Jones RP; Knott PJ; Marsden CD; Tattersall R; Vollum D
    Lancet; 1971 May; 1(7709):1083-6. PubMed ID: 4102620
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease].
    Hacohen H; Gurtner B
    Schweiz Med Wochenschr; 1972 Apr; 102(16):583-6. PubMed ID: 5019377
    [No Abstract]   [Full Text] [Related]  

  • 13. Amantadine in the treatment of Parkinson's disease.
    Schwab RS; England AC; Poskanzer DC; Young RR
    JAMA; 1969 May; 208(7):1168-70. PubMed ID: 5818715
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
    Bauer RB; McHenry JT
    Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa and amantadine in the therapy of parkinsonism.
    Weeth JB; Shealy CN; Mercier DA
    Wis Med J; 1969 Nov; 68(11):325-8. PubMed ID: 4901055
    [No Abstract]   [Full Text] [Related]  

  • 16. Parkinson's disease and amantadine hydrochloride.
    JAMA; 1969 May; 208(7):1180-1. PubMed ID: 5818720
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes].
    Ciuca I; Bulandra R; Serbanesco A; Ninosu N
    Rev Neurol (Paris); 1972 Aug; 127(2):305-8. PubMed ID: 4672049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.